Skip to main content

Table 2 CPIC Rating and IGNITE Member Sites Using pharmacogenomics testing for Research, Clinical Reporting and Billing/Reimbursement Methods (N = 15)

From: Translating pharmacogenetics from research to routine clinical practice – a survey of the IGNITE Network

CPIC A/B (N= 17 genes)

 

Finances of clinical testing

 

Used in RESEARCH

Used CLINICALLY

Billing patients

Billing 3rd party

Other sources of funding

Total

11

15

2

11

8

% of PGx Testing sites

73%

100%

13%

73%

53%

CPIC C/D (N= 8 genes)

 

Finances of clinical testing

 

Used in RESEARCH

Used CLINICALLY

Billing patients

Billing 3rd party

Other sources of funding

Total

7

2

1

1

3

% of PGx Testing sites

47%

13%

7%

7%

20%

No CPIC Rating (N= 15 genes)

 

Finances

 

Used in RESEARCH

Used CLINICALLY

Billing patients

Billing 3rd party

Other sources of funding

Total

7

4

1

1

5

% of PGx Testing sites

47%

27%

7%

7%

33%